RPRX

In March 2026, Royalty Pharma partnered with Johnson & Johnson, providing $500 million for autoimmune medicine development. In January 2026, the company acquired a royalty interest in Ziihera from Zymeworks for $250 million and committed up to $500 million to co-fund a Teva Pharmaceuticals program for vitiligo. In August 2026, Royalty Pharma reported Q2 earnings, beating EPS estimates ($1.32 vs. $1.27 consensus) despite a revenue miss, and confirmed a $0.235 quarterly dividend payable in September. Analyst sentiment has been broadly bullish, with several firms reiterating 'Buy' ratings and raising price targets. However, in early September 2026, the company announced that Novartis' Phase 3 HORIZON outcomes trial for pelacarsen, in which Royalty Pharma held an indirect financial interest, did not meet its primary endpoint, causing a modest slip in shares. Despite this, management reiterated expectations to recoup its investment and earn a modest positive return due to the deal's structure, and reaffirmed its 2030 Portfolio Receipts target of at least $4.7 billion. The stock has shown strong performance over the past year, increasing by 60.63% and 64.6% over the past year and 29.4% in the last six months.